History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)

MDMA, known as the illicit drug ecstasy, shows promise when used alongside psychotherapy for posttraumatic stress disorder (PTSD), though how it works remains unclear. This review traces MDMA's path from military interrogation aid to prohibited substance and now to clinical use. The authors identify three core subjective effects—prosocial behavior, reduced threat perception, and euphoria—and examine how each may contribute to both therapeutic benefits and abuse potential. They emphasize serotonin's central role in MDMA's effects while noting gaps in understanding its mechanism. The review also critiques preclinical models, highlights limitations like sex biases and assumptions about therapeutic alliance, and calls for clarifying mechanisms to develop safer, more effective MDMA-like treatments.

Study at a glance

Abstract

The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic stress disorder (PTSD), although the underlying mechanisms are poorly defined. In this review, we contextualize the emergence of MDMA-assisted psychotherapy (MDMA-AT) within 20th century psychiatry and trace its journey from assisting with military interrogation, through prohibition and to clinical use. We outline three core domains of MDMA's subjective effects-prosocial behaviour, reduced threat perception and euphoria-and explore how each may relate to its therapeutic efficacy and abuse liability. Drawing from clinical, behavioural, and pharmacological studies, we highlight the central role of 5-HT (serotonin) in mediating the effects of MDMA, while identifying key gaps in our understanding of its mechanism of action. We also assess how preclinical models capture therapeutic-relevant processes, discuss the limitations of existing data (including sex biases and an assumed role for therapeutic alliance) and suggest strategies to unravel the neurobiological basis of MDMA's therapeutic effects. Clarifying these mechanisms will be critical for optimizing future clinical protocols, mitigating risks and guiding the clinical development of safer, mechanistically informed MDMA-like therapeutic agents.